secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0000950170-24-041619
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports CAN-2409 phase 2 interim data: median OS 28.8 vs 12.5 months in pancreatic cancer
--------------------------------------------------------------------------------

- Estimated median overall survival 28.8 months for CAN-2409 group vs 12.5 months for control in borderline resectable PDAC.
- 24-month survival rate 71.4% for CAN-2409 vs 16.7% control; 36-month rate 47.6% vs 16.7%.
- 4 of 7 CAN-2409 patients alive at data cut-off (2 >50 months); only 1 of 6 control alive.
- Immune activation confirmed: dense CD8+ TILs, dendritic cells, B cells in tumor; increased granzymes and IFN-γ in blood.
- No dose-limiting toxicities or pancreatitis; FDA Fast Track Designation granted in December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024041619/0000950170-24-041619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024041619/cadl-20240404.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-041619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer